Monoclonal antibodies in the treatment of chronic lymphocytic leukemia
- PMID: 15579912
- DOI: 10.1385/MO:21:4:297
Monoclonal antibodies in the treatment of chronic lymphocytic leukemia
Abstract
Traditional therapy for chronic lymphocytic leukemia (CLL) has consisted of alkylating agents, purine analogs, or a combination of these drugs. These agents are effective at producing remissions but are not curative.Thus, new drugs are still needed to improve the outcome of patients with CLL. The introduction of monoclonal antibodies, such as rituximab and alemtuzumab, provides a novel therapeutic modality.Rituximab is an active agent in CLL. Standard doses of rituximab result in higher response rates in previously untreated than in relapsed patients but low complete response (CR) rates. Rituximab is most effective in combination with chemotherapy, especially fludarabine-based regimens in the first-line and salvage setting. Rituximab is also useful in the treatment of complications of CLL, such as pure red cell aplasia, autoimmune thrombocytopenia, and autoimmune hemolytic anemia. Alemtuzumab has impressive activity in patients with refractory CLL and may play an important role in the consolidation treatment of CLL. Alemtuzumab is most efficacious at clearing disease in the peripheral blood and bone marrow. Bulky lymphadenopathy is less sensitive to therapy. Because of the significant lymphopenia associated with alemtuzumab, antibacterial and antiviral prophylaxis should always be used.
Similar articles
-
A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL).Leuk Lymphoma. 2004 Nov;45(11):2269-73. doi: 10.1080/10428190412331286096. Leuk Lymphoma. 2004. PMID: 15512816 Clinical Trial.
-
Therapy of chronic lymphocytic leukemia with purine analogs and monoclonal antibodies.Transfus Apher Sci. 2005 Feb;32(1):33-44. doi: 10.1016/j.transci.2004.10.004. Transfus Apher Sci. 2005. PMID: 15737872 Review.
-
Evolving role of monoclonal antibodies in the treatment of chronic lymphocytic leukemia.Expert Opin Investig Drugs. 2007 Nov;16(11):1799-815. doi: 10.1517/13543784.16.11.1799. Expert Opin Investig Drugs. 2007. PMID: 17970639 Review.
-
Monoclonal antibodies in the treatment of chronic lymphoid leukemias.Leuk Lymphoma. 2004 Feb;45(2):205-19. doi: 10.1080/1042819031000139666. Leuk Lymphoma. 2004. PMID: 15101704 Review.
-
The clinical application of monoclonal antibodies in chronic lymphocytic leukemia.Blood. 2010 Nov 11;116(19):3705-14. doi: 10.1182/blood-2010-04-001230. Epub 2010 Jul 7. Blood. 2010. PMID: 20610811 Free PMC article. Review.
Cited by
-
Living donor renal transplantation using alemtuzumab induction and tacrolimus monotherapy.Am J Transplant. 2006 Oct;6(10):2409-17. doi: 10.1111/j.1600-6143.2006.01495.x. Epub 2006 Aug 4. Am J Transplant. 2006. PMID: 16889606 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources